CXCL13 is involved in the control of cancer cell phenotypes and play an important role in the progression and metastasis of solid tumor (75). Furthermore, a recent study revealed its function in maintaining the antitumor environment and supported clinical investigation on the combination of CXCL13 and PD-1 blockade therapy for high-grade serous ovarian cancer (76). Accordingly, the ARG score model comprised of these four genes has the potential to predict the clinical outcomes and immunotherapy response of OV patients. The gene discussed is CXCL13; the disease is ovarian serous adenocarcinoma.